TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT06357702

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Physical Self Regulation Telehealth
Description: 2 sessions of an intervention delivered via telehealth. Session 1 includes awareness and strategies for monitoring habits and 4 exercises to practice 5 times per day. Session 2 will be 2 weeks later and is a review of session 1 and an introduction to diaphragmatic breathing. Breathing is practiced for 15 minutes twice per day.

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Psycho-education Telehealth
Description: 2 sessions of an intervention delivered via telehealth. Session 1 includes discussing trigeminal nerve function, jaw and muscle anatomy, posture, pain referral patterns, and stress biology. Participants rate pain and jaw fatigue 5 times per day. Session 2 will be 2 weeks later and consists of checking on the homework and information from session 1,followed by a discussion of autonomic nervous system activity, and a discussion of sleep quality and sleep hygiene. Participants will be instructed to rate their stress levels, pain, and mood several times per day, similar to the times when participants in the PSR-TH condition would be practicing diaphragmatic breathing
Study: NCT05474677

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: closure of the abdominal fascia
Description: The abdomen will be closed in intervention group with continuous PDS 2\\0 sutures and size zero in control group.

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: closure of the abdominal fascia
Description: The abdomen will be closed in intervention group with continuous PDS 2\\0 sutures and size zero in control group.
Study: NCT05664945

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: pulmonary tele-rehabilitation (PTR)
Description: PTR is delivered from promoter hospital to a group of 4-6 patients who exercise at home and communicate via tablet-camera.~Each session is 60 min; 35 min exercise/ 25 min patient education, two times per week for a duration of 10-weeks (primary endpoint).~Specific exercises are evidence-based; been used in several intervention studies on patients with COPD.~Exercises involves larger muscle groups with 50/50 exercises for upper and lower extremities. Volume, intensity and content exercise protocol follow both national and international exercise recommendations.~The education sessions consist of dialogue, reflections around empowerment and better living with COPD.~Every fourth education session consists of 25 min Mindfulness exercises developed for COPD patients.~After 10-weeks of PTR, participants are offered once weekly PTR for 60min in groups of 4-8 persons throughout a 65-week maintenance period (secondary endpoint 75-weeks from baseline).

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: home-based pulmonary rehabilitation (HPR)
Description: HPR is an individual self-initiated home-based PR aiming to achieve 20 min of self-initiated muscle-endurance based exercise; 3-days/weekly for 10-weeks (primary endpoint).~Exercises are evidence-based; used in several intervention studies on patients with COPD and involves larger muscle groups with 50/50 exercises for upper/lower extremities.~First session is a home visit by a respiratory physiotherapist. During the visit the physiotherapist and patient establish exercise goals, exercise prescription and provision of mindfulness exercises and educationbook.~The home visit is followed by one weekly session for 10-weeks. A menu of topics relevant to COPD and self-management is discussed. A session is delivered from promoter hospital via tablet-camera or telephone call (patients' preference).~After 10-weeks of HPR, participants are offered once weekly PTR for 60min in groups of 4-8 persons throughout a 65-week maintenance period (secondary endpoint 75-weeks from baseline).

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Control
Description: Receive usual care; medication, scheduled follow-up visit and possible phone contact with GP and the outpatient respiratory department.~Except for assessment visits 10-, 35-, and 75-weeks from baseline no intervention is offered.~If a patient changes his/her mind and wishes to participate in a conventional hospital- or community-based PR program, it will be granted as this is a highly recommended treatment (e.g. rehabilitation after hospital admitted exacerbation).
Study: NCT06190119

Intervention type: OTHER
Intervention: none intervention
Description: This study has no intervention

Intervention type: OTHER
Intervention: none intervention
Description: This study has no intervention
Study: NCT05349123

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Mindful Breathing
Description: Subject will be expected to do 12 weeks of home-based rehabilitation, 6 days a week in their home. The proposed project explores the addition of a mindful breathing module, which involves daily guided breathing practice with feedback to encourage mindful breathing.

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Home-Based Pulmonary Rehabilitation
Description: Subject will be asked to complete exercise guided by a video six days a week and to complete mindful walking six days per week. They will receive weekly health coaching calls.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Home-Based Pulmonary Rehabilitation
Description: Subject will be asked to complete exercise guided by a video six days a week and to complete mindful walking six days per week. They will receive weekly health coaching calls.
Study: NCT05587647

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Transition to Adulthood Education Program
Description: YEGEP was developed by the authors based on the information in the literature, based on the needs of mothers of children who have reached adulthood or are going through. Three training modules are planned in line with current requirements. Education will also be supported by audio-visual and written materials. It is planned that the trainings, which will last for 3 weeks in total, for 1 hour a week for each group, in the form of 3 sessions of 1 hour with these contents, will be held at a disabled center. Titles of training modules:~1. Developmental Period Characteristics of Young Adults with Intellectual Disabilities (Transition to Adulthood, Future Planning / Social Life (employment, peers, etc.)~2. Protecting and Sustaining the Health of Young Adult with Intellectual Disabilities~3. Coping with Stress
Study: NCT05404841

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: CoffeeBerry Supplement
Description: A Coffeeberry supplement containing 200mg Caffeine and 14mg polyphenols, manufactured by FutureCeuticals Inc.,

Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo
Study: NCT05229874

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: carbon nanoparticles
Description: Endoscopic injection

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Indocyanine green
Description: Endoscopic injection
Study: NCT05076513

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Niraparib
Description: In Phase 0, 300mg administered orally QD for 4 days prior to resection.~In the Expansion cohort/Maintenance phase, niraparib will be administered as described below:~* For patients weighing \<77 kg (\<170 lbs) OR with a platelet count \<150,000/mcL, the recommended dosage is 200 mg taken orally once daily.~* For patients weighing ≥77 kg (≥170 lbs) AND a platelet count ≥150,000/ mcL, the recommended dosage is 300 mg taken orally once daily.

Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: Radiation therapy
Description: Participants in Arm A who move onto the Expansion cohort will receive 6-7 weeks of radiation therapy per standard of care.
Study: NCT05248997

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: rimegepant 75 mg ODT
Description: One dose of rimegepant 75 mg ODT

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Matching placebo
Description: One dose of matching placebo
Study: NCT05312229

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Critical Time Intervention
Description: An evidence-based, structured, and time-limited case management practice
Study: NCT06313216

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: duoteck membrane
Description: the dehisced bone defect will be covered with duoteck membrane

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: autogenous demineralized tooth graft
Description: the dehisced bone defect will be covered with autogenous demineralized tooth graft

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: autogenous demineralized tooth graft and plate
Description: the dehisced bone defect will be covered with autogenous demineralized tooth graft combined with autogenous demineralized tooth plate
Study: NCT06297304

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Sedentary and physical activity behaviors
Description: The intervention will consist of three individual sessions, each lasting one hour, with approximately 15 days between each session. The sessions will be scheduled as follow: Week 5 and 6 (session 1), week 7 and 8 (session 2), week 9, 10, and 11 (session 3). During these sessions, subjective and objective indicators related to sedentary behaviors and the physical activity levels will be recorded to assess the progress of each student.
Study: NCT04632147

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Ujjayi pranayama, Nadi-Shodhana pranayama, Sukha pranayama
Description: Ujjayi pranayama:It is a pranayamic application that is performed by slightly twisting the throat and breathing through the nose. Nadi shodhana pranayama is breathing alternately through the right and left nostrils.Sukha pranayama is inhaled through the nose for 5 seconds, then given through the nose for 5 seconds. Thus, 6 times of inspiration and expiration is done per minute.
Study: NCT04881539

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Cannabidiol (CBD)
Description: This group will receive an oral dose of CBD (Six Degrees Wellness).
Study: NCT05374057

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Ibuprofen
Description: See study arm.

Intervention type: DRUG
Group type: SHAM_COMPARATOR
Intervention: Placebo medication
Description: See study arm.
Study: NCT04881539

Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Cannabidiol (CBD)
Description: This group will receive an oral dose of CBD (Six Degrees Wellness).
Study: NCT04803812

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Remote SMS (short message service, also known as text message) delivery
Description: Assessing the comparative effects of SMS types (storytelling; resources/strategies; and a combination of both) on physician wellbeing.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Remote SMS (short message service, also known as text message) delivery
Description: Assessing the comparative effects of SMS types (storytelling; resources/strategies; and a combination of both) on physician wellbeing.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Remote SMS (short message service, also known as text message) delivery
Description: Assessing the comparative effects of SMS types (storytelling; resources/strategies; and a combination of both) on physician wellbeing.
Study: NCT06187818

Intervention type: DRUG
Intervention: Crocin
Description: According to the patient's condition, tolerance level, and personal preference, the dosage of medication was selected. During chemotherapy, the total anthocyanin tablets were divided into an experimental group (experimental group 1 and experimental group 2 based on previous heart disease) and a control group (control group 1 and control group 2 based on previous heart disease), 30 cases in each group \[experimental group: taking saffron total glycoside tablets for 8 days during each chemotherapy period (starting from the day before chemotherapy), 4 tablets/time, 3 times a day; control group: not taking saffron total glycoside tablets during chemotherapy period\]

Intervention type: DRUG
Intervention: Crocin
Description: According to the patient's condition, tolerance level, and personal preference, the dosage of medication was selected. During chemotherapy, the total anthocyanin tablets were divided into an experimental group (experimental group 1 and experimental group 2 based on previous heart disease) and a control group (control group 1 and control group 2 based on previous heart disease), 30 cases in each group \[experimental group: taking saffron total glycoside tablets for 8 days during each chemotherapy period (starting from the day before chemotherapy), 4 tablets/time, 3 times a day; control group: not taking saffron total glycoside tablets during chemotherapy period\]
Study: NCT05312229

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Critical Time Intervention
Description: An evidence-based, structured, and time-limited case management practice

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: External Facilitation
Description: Site-specific support to help sites develop tailored plans to implement CTI.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Replicating Effective Programs
Description: A stakeholder-informed training and technical assistance implementation strategy

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Replicating Effective Programs
Description: A stakeholder-informed training and technical assistance implementation strategy
Study: NCT06000657

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Vemliver tablet
Description: Chronic Hepatitis B Patients Who Pretreated with Entecavir switching to Vemliver tab (Tenofovir Alafenamide Hemitartrate)

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Baracross Tablet
Description: Chronic Hepatitis B Patients Who Pretreated with Entecavir continuting treatement with Baracross Tablet
Study: NCT05407714

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: SpaceOAR Treatment
Description: SpaceOAR System is intended to temporarily position the anterior rectal wall away from the prostate during radiotherapy for prostate cancer and in creating this space it is the intent of SpaceOAR System to reduce the radiation dose delivered to the anterior rectum.~The SpaceOAR System is composed of biodegradable material and maintains space for the entire course of prostate radiotherapy treatment and is completely absorbed by the patient's body over time.
Study: NCT05104463

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: CST-2032, matching placebo for CST-2032, CST-107, matching placebo for CST-107
Description: CST-2032 and matching placebo white tablets, CST-107 and matching placebo yellow tablets

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: CST-2032, matching placebo for CST-2032, CST-107, matching placebo for CST-107
Description: CST-2032 and matching placebo white tablets, CST-107 and matching placebo yellow tablets
Study: NCT06071234

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: 3D reconstruction technology
Description: Preoperative application of 3D reconstruction technology to evaluate the breast blood supply of participants and observe whether the incidence of ischemic complications in the flap and nipple areola complex is reduced compared to surgery without preoperative evaluation.

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: 3D reconstruction technology
Description: Preoperative application of 3D reconstruction technology to evaluate the breast blood supply of participants and observe whether the incidence of ischemic complications in the flap and nipple areola complex is reduced compared to surgery without preoperative evaluation.
Study: NCT05240898

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: RO7623066
Description: Administered orally in capsule

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: RO7623066
Description: Administered orally in capsule

Intervention type: DRUG
Group type: OTHER
Intervention: RO7623066
Description: Administered orally in capsule

Intervention type: DRUG
Group type: OTHER
Intervention: RO7623066
Description: Administered orally in capsule

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: RO7623066
Description: Administered orally in capsule

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Olaparib
Description: Administered orally.~Dose levels and schedules will be selected based on integration of preclinical data as well as clinical PK, safety, efficacy, and PD/biomarker data (as appropriate) from the dose escalation cohorts.

Intervention type: DRUG
Group type: OTHER
Intervention: Olaparib
Description: Administered orally.~Dose levels and schedules will be selected based on integration of preclinical data as well as clinical PK, safety, efficacy, and PD/biomarker data (as appropriate) from the dose escalation cohorts.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Carboplatin
Description: Administered intravenously.
Study: NCT04838522

Intervention type: OTHER
Intervention: No Intervention
Description: This is a non-interventional study.
Study: NCT06278415

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Physiological based cord clamping
Description: see Arm Description

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Differed cord clamping
Description: see Arm Description
Study: NCT05101837

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Home program
Description: Regular mindfulness guided face-to-face program, by using the technology with android to receive mindfulness sessions for daily practice and to assess the feasibility and the effectiveness of behavioural approach base on mindfulness delivered with this modality
Study: NCT06517784

Intervention type: OTHER
Intervention: No treatment given
Description: No treatment given

Intervention type: OTHER
Intervention: No treatment given
Description: No treatment given
Study: NCT06577558

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: SR1375 capsule 3mg+regular treatments
Description: SR1375 capsule 3mg QD orally+CAP regular treatments

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: SR1375 capsule 1mg+regular treatments
Description: SR1375 capsule 1mg QD orally+CAP regular treatments

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: SR1375 capsule 0.3mg+regular treatments
Description: SR1375 capsule 0.3mg QD orally+CAP regular treatments

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo capsule+regular treatments
Description: Placebo capsule QD orally+CAP regular treatments
Study: NCT06578559

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cetuximab
Description: 500 mg/sqm intravenous infusion over 120-minute at cycle 1 (if well tolerated, it is administered over 90 minutes at second administration, and over 60 minutes by the third administration) every 14 days.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Encorafenib
Description: 300 mg once daily (four 75 mg oral capsules).
Study: NCT05667532

Intervention type: DIAGNOSTIC_TEST
Intervention: Contrast Enhanced Mammography
Description: Screening Modality
Study: NCT06145022

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: lifestyle modification
Description: The group intervention is carried out once a week for 10 weeks for a total of 60 hours with elements of mindfulness-based stress reduction (MBSR) and mind / body medicine. In this project, this program will be adapted to the specific needs of irritable bowel syndrome patients.

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: waitlist control group
Description: Participants in this group receive a one-time education unit within the scope of 1,5 hours on the influence of lifestyle factors on the disease, also self-help materials for independent training offered. Following the follow-up measure also this group is given the opportunity to participate in the multimodal stress reduction- and lifestyle modification program.
Study: NCT06238791

Intervention type: OTHER
Intervention: Presence of foot deformity, ankle range of motion, foot posture, local tissue water percentage, and foot pressure distribution will be evaluated in patients with chronic venous disease.
Description: Presence of foot deformity, ankle range of motion, foot posture, local tissue water percentage, and foot pressure distribution will be evaluated in patients with chronic venous disease and lipedema.

Intervention type: OTHER
Intervention: Presence of foot deformity, ankle range of motion, foot posture, local tissue water percentage, and foot pressure distribution will be evaluated in patients with chronic venous disease.
Description: Presence of foot deformity, ankle range of motion, foot posture, local tissue water percentage, and foot pressure distribution will be evaluated in patients with chronic venous disease and lipedema.
Study: NCT05008887

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Methotrexate
Description: Fractional CO2 laser-assisted cutaneous delivery of methotrexate solution in stable, non-segmental vitiligo

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: 5-fluorouracil
Description: Fractional CO2 laser-assisted cutaneous delivery of 5-fluorouracil solution in stable, non-segmental vitiligo
Study: NCT05865769

Intervention type: OTHER
Intervention: Balance
Description: measuring pulmonary and vestibular functions in all subjects

Intervention type: OTHER
Intervention: Balance
Description: measuring pulmonary and vestibular functions in all subjects
Study: NCT05008887

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Fractional CO2 laser
Description: Fractional CO2 laser-assisted cutaneous delivery of methotrexate and 5-fluorouracil solution in stable, non-segmental vitiligo

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Fractional CO2 laser
Description: Fractional CO2 laser-assisted cutaneous delivery of methotrexate and 5-fluorouracil solution in stable, non-segmental vitiligo
Study: NCT06485804

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Smartphone application guided exercises
Description: Participants in the intervention group will use a smartphone application to execute a self-rehabilitation program. The app will integrate:~* Basic information about neck pain and ergonomic advice.~* A series of evaluation questions on pain and function.~* Appropriate sets of exercises with videos and instructions.~* Daily reminders.~* Evaluation reports providing feedback and adherence.
Study: NCT06576323

Intervention type: BEHAVIORAL
Group type: OTHER
Intervention: An implementation model for co-located Medications for Opioid Use Disorder (MOUD) prescription in the NICU
Description: We will use implementation mapping to develop a suite of implementation strategies to deliver evidence-based MOUD prescription to mothers attending the bedside of their infants hospitalized in the NICU. The intervention itself is buprenorphine induction and treatment, however the model for delivery is not yet developed, consistent with the need for results from Aim 1 to inform the approach used to develop the implementation model in Aim 2.